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Inhibiting the renin-angiotensin system has proven to be
one of the most fruitful therapeutic strategies in cardiovas-
cular medicine. Believed to have evolved to maintain blood
volume and perfusion pressure in conditions of hemorrhage
or hypovolemia, the renin-angiotensin-aldosterone system
(RAAS) is upregulated in the setting of left ventricular (LV)
dysfunction or heart failure (1). Pharmacologic inhibitors of
this system—including renin inhibitors, angiotensin-
converting enzyme (ACE) inhibitors, aldosterone antago-
nists, and angiotensin receptor blockers—were all initially
designed for the treatment of hypertension, and, with the
exception of renin inhibitors, are currently clinically used for
this indication. Nevertheless, the benefits of inhibiting the
RAAS have extended well beyond this initial therapeutic
target.
See page 1666
Animal models of ventricular dysfunction and heart
failure provided the initial impetus for early clinical work
demonstrating the unique hemodynamic benefits of ACE
inhibitors (2–5). These animal and early clinical experi-
ments were followed by placebo-controlled trials in late
1980s and early 1990s, which demonstrated that treatment
with ACE inhibitors reduced morbidity and mortality in
both heart failure and post-myocardial infarction patients
(6–11). In these studies, ACE inhibitors were used in
addition to conventional therapy, which was at the discre-
tion of the treating physician. Because few agents had
demonstrated benefit in these clinical settings, ACE inhi-
bition became almost required therapy when tolerated for
patients with heart failure or myocardial infarction (MI)
complicated by heart failure or LV dysfunction (12,13).
By the late 1990s, there was increasing interest in
alternative and complementary methods for inhibiting the
RAAS in patients with cardiovascular disease. New clinical
trials were initiated in patients with heart failure or follow-
ing infarction to test two separate classes of RAAS inhibi-
tors—the newly developed angiotensin receptor blockers
(14–16) and the previously available aldosterone antagonist
spironolactone. The ELITE II trial directly compared an
angiotensin receptor blocker to an ACE inhibitor in heart
failure patients, yet it failed to show a mortality benefit to
receptor blockade over ACE inhibition. The ValHEFT
trial, in contrast, was designed to assess the benefit of adding
an angiotensin receptor blocker to conventional therapy in
heart failure, which included ACE inhibition in the major-
ity of patients (16). Although concerns about the safety of
combination therapy remained, mechanistic evidence sug-
gested a potential benefit of adding an angiotensin receptor
blocker to an ACE inhibitor in heart failure (17). Further-
more, the phenomenon of angiotensin and aldosterone
“escape,” in which both angiotensin and aldosterone levels,
initially lowered by ACE inhibition, would eventually in-
crease to pretreatment levels, was well known (18,19).
Despite these potential benefits of combined therapy, the
ValHEFT trial did not demonstrate a survival benefit with
valsartan added to conventional therapy, although the ad-
dition of valsartan resulted in a clear reduction in the
incidence of heart failure. The recently reported Candesar-
tan in Heart Failure (CHARM) trial, further demonstrates
the clinical benefit of adding an angiotensin receptor blocker
to standard therapy in heart failure patients (20).
Despite the fact that spironolactone had been successfully
used in the treatment of hypertension for some time (21), it
had not been tested in a broader range of cardiovascular
disorders. The first major trial to assess the use of an
aldosterone antagonist in patients with LV dysfunction, the
Randomized Aldactone Evaluation Study (RALES), as-
sessed the effect of spironolactone compared with placebo
among optimally managed heart failure patients (22). Mor-
tality was reduced by 30% in patients treated with spirono-
lactone. This finding, however, was met with some reser-
vation in the general cardiology community. Inhibiting the
aldosterone receptor was believed to confer only partial
inhibition of the RAAS. Angiotensin II (ang II), rather
than aldosterone, was thought to mediate most of the
deleterious effects of RAAS activation. In addition to its
vasoconstrictor effect, ang II is recognized to promote
vascular smooth muscle cell growth and proliferation and
myocyte hypertrophy (23). Traditionally, the effects of
aldosterone inhibition were thought to be primarily in the
kidney, where aldosterone stimulates retention of sodium
and water and secretion of potassium in the distal tubule.
Yet a growing body of evidence suggests that aldosterone,
like angiotensin, mediates a variety of actions throughout
the cardiovascular system and may play a role in cardiac and
vascular fibrosis and ventricular remodeling (24–27). Aldo-
sterone, like ang II, stimulates fibroblast growth and syn-
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thesis of fibrillar collegen (28). Additionally, aldosterone
induces both oxidative stress and a proinflammatory re-
sponse, an effect that can be attenuated with spironolactone
(29).
Many therapies that have proven beneficial in heart
failure patients have also shown benefit in patients following
MI. This is in part due to the fact that a large percentage of
heart failure patients are survivors of MI and that many of
the neurohormonal systems—including the RAAS—that
are activated in heart failure are also activated following
infarction. Additionally, the RAAS has been implicated in
healing and remodeling following MI: angiotensin is di-
rectly involved in collagen synthesis and breakdown path-
ways (30) and may mediate post-MI tissue repair (31).
In this issue of the Journal, a report by Fraccarollo et al.
(32) furthers our understanding of the role of aldosterone
receptor blockade following MI. Eplerenone, a selective
aldosterone receptor antagonist with fewer side effects than
spironolactone (33,34), was compared in a rat MI model
with placebo, the ACE inhibitor trandolapril, or a combi-
nation of eplerenone and trandolapril. There were signifi-
cant hemodynamic benefits to treatment with eplerenone
and even greater benefits with the combination of agents.
These hemodynamic improvements included a decrease in 
(tau), the time constant of relaxation, a reduction in end-
diastolic volume and pressure, and, most importantly, a
substantially leftward shift of the pressure-volume loops
with an overall reduction in LV remodeling. In addition,
these mechanistic data provide important insight into the
cellular and biochemical mechanisms of the incremental
benefit of aldosterone receptor blockade. Both collagen type
I gene expression and collagen content in the noninfarcted
myocardium were decreased by ACE inhibition, but the
normally observed increases in collagen content following
infarction were essentially abolished by eplerenone or the
combination of eplerenone and trandolapril. Combination
therapy additionally prevented SERCA2 and ATPase
downregulation, and decreased both beta-myosin heavy
chain and atrial natriuretic factor gene expression.
The results of this study (32) are of particular importance
in light of the recently published EPHESUS trial (35). In
this double-blind, placebo-controlled study, eplerenone was
compared to placebo in patients with LV dysfunction
following infarction who were already receiving standard
therapy. Treatment with eplerenone led to a 15% reduction
in overall mortality and a 17% reduction in cardiovascular
deaths in patients treated with eplerenone. Heart failure was
reduced by 23%, and sudden death by 21%, in the
eplerenone group. Of note, 87% of patients enrolled were
already being treated with ACE inhibitors and 75% received
beta-blockers, indicating that the aldosterone inhibitor in-
deed provided incremental benefit to optimal therapy.
The RALES and EPHESUS studies firmly establish the
incremental value of aldosterone receptor blockade in pa-
tients with heart failure and high-risk MI. The results of the
Fraccarollo study (32) along with those of EPHESUS,
demonstrate the bidirectionality of the bench-to-bedside
model. Just as clinicians are being challenged to evaluate
new therapies on background use of other proven agents,
this animal study has adopted a similar experimental design
to assess the incremental value of an aldosterone antagonist
in the setting of ACE inhibition. In this case, the rat infarct
model, which provided much of the rationale for clinical use
of ACE inhibitors used in heart failure and following
infarction, has offered important basic insights into the
results of a clinical trial. Taken together, the clinical trial
and experimental results provide a compelling rationale for
combined approaches to inhibiting the renin-angiotensin
aldosterone system after infarction.
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